John Cox, Dyne Therapeutics CEO
May 20, 2024 11:35 AM EDT
R&D

Dyne Ther­a­peu­tics sharp­ens case for two mus­cle dis­ease ther­a­pies with up­dat­ed da­ta 

Lei Lei Wu

News Reporter

Dyne Ther­a­peu­tics shared promis­ing clin­i­cal tri­al up­dates from two of its ex­per­i­men­tal RNA med­i­cines for my­oton­ic dy­s­tro­phy type 1 (DM1) and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Mod­er­na plans $1.1B in R&D and pro­gram cuts, de­lays break-even point to 2028

Sofinno­va’s Jim Healy on ‘more ra­tio­nal mar­ket’ as four biotech star­tups near their IPOs

Seres' mi­cro­bio­me ther­a­py re­duces in­fec­tions in stem cell trans­plant pa­tients, but next steps are un­clear

Charles Riv­er to lay off 3% of staffers as it stream­lines spend­ing

Sanofi buys in­to ra­dio­phar­ma­ceu­ti­cal field with $110M up­front, go­ing af­ter space held by No­var­tis

A new start­up wants to fight can­cer with 'off-the-shelf' gene ther­a­py, se­cur­ing $26M seed round

A service from the Financial Times